Psychopathy is a disorder characterized by lack of empathy and remorse, antisocial behavior, increased tendencies towards aggression and anger, and blunted anticipatory fear.
Exploring the companies and themes that make up this emerging and exciting new sector
Psychedelics Decriminalization Advancing In Three More Cities, Spanning From Coast To Coast
From Massachusetts to California, advocates are actively making new strides to reform local laws governing psychedelics like psilocybin and ayahuasca—building on a national movement that has already seen numerous cities decriminalize entheogenic substances.
DEA Says Cancer Patients’ Request For Medical Psilocybin Could Fuel Illegal Drug Market
The U.S. Drug Enforcement Administration is asking a federal appeals court to throw out a lawsuit aimed at clearing a path to the therapeutic use of psilocybin, the main psychoactive compound in psychedelic mushrooms—arguing that allowing limited medical access could boost the illegal drug trade.
Will The Covid-19 Pandemic Be A Turning Point For Psychedelic Medicine?
The Mental Health Crisis has been ignored for decades. Covid-19 has made this mental health catastrophe much worse -- and people are now starting to notice.
MindMed Announces Initiation of Phase 1 Clinical Trial of Intravenous DMT
MindMed is preparing to commence a Phase I clinical trial on the safety/tolerance of intravenous DMT.
Cybin Announces Size and Pricing of Previously Announced Overnight Marketed Public Offering of Common Shares
Cybin's new financing is priced at CAD$3.40. The Company intends to issue 8.8 million new units for total proceeds of CAD$30 million.
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
Atai Life Sciences announces the launch of a new intranasal drug delivery system, InnarisBio, based on sol-gel technology.
Cybin Announces Overnight Marketed Public Offering of Common Shares
Cybin Inc is seeking to raise capital with an overnight offering of common shares. Pricing and size of the offering to be determined.
MINDCURE Launches Second Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research
MINDCURE's proprietary ibogaine manufacturing has reached the second stage of development: assessing the quality of its synthetic ibogaine.
Field Trip Health Ltd. to Commence Trading on the NASDAQ on July 29, 2021 Under the Symbol FTRP
Field Trip Health to commence trading on the NASDAQ on July 27th under the symbol "FTRP".
MDMA-assisted cognitive-behavioral therapy may help couples overcome PTSD
Post-traumatic stress disorder affects roughly 7 million people in the United States alone.
Substance Abuse: Global Plague, A Pot Of Gold For Psychedelic Stocks
We explain why addiction therapy likely offers the greatest long-term commercialization potential within the psychedelic drug industry.